Clinical trials: HER2 + Gastric Cancer
HER2 Expressing Solid Tumors
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
- Trial name
- SENTRY-HER2 (NCT07192432)
- Testing
- Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202
- Where
- 11 sites in United States
- Volunteers
- 27 people
- Sponsor
- Vironexis Biotherapeutics Inc.
HER2 Expressing Breast or Gastric/Stomach Cancers
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.
- Trial name
- MEDI4276 (NCT02576548)
- Testing
- MEDI4276
- Where
- 5 sites in United States
- Volunteers
- 47 people
- Sponsor
- MedImmune LLC
Gastric Cancer
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer
The purpose of this early proof-of-concept study to evaluate the safety and immunologic efficacy of AST-301 in gastric cancer patients with HER2 expression (including both HER2 low expression and overexpression) who have…
- Trial name
- Conerstone3 (NCT05771584)
- Testing
- AST-301, rhuGM-CSF
- Where
- 6 sites in Taiwan
- Volunteers
- 24 people
- Sponsor
- Aston Sci. Inc.